REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Scientists test new drug duo in fight against stubborn lymphoma
Disease control OngoingThis early-stage study is testing the safety and best dose of a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has come back or stopped responding to other treatments. The goal is to see if this drug pair can help control the cancer and is sa…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Virus + drug combo tested for Tough-to-Treat skin cancers
Disease control OngoingThis study is testing a two-part treatment for patients with advanced skin cancers or rare lymphomas that have not responded to other therapies. First, a modified virus is injected directly into tumors to help the immune system recognize cancer. Then, an immunotherapy drug is giv…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New drug duo tested to fight aggressive blood cancer
Disease control OngoingThis study is testing a combination of two drugs, pembrolizumab and romidepsin, for people with a type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if using these drugs together is safe and mor…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC